tiprankstipranks
Trending News
More News >
Sintx Technologies Inc (SINT)
NASDAQ:SINT
Advertisement

Sintx Technologies (SINT) AI Stock Analysis

Compare
1,019 Followers

Top Page

SINT

Sintx Technologies

(NASDAQ:SINT)

Select Model
Select Model
Select Model
Neutral 45 (OpenAI - 4o)
Rating:45Neutral
Price Target:
$3.50
▼(-15.66% Downside)
Sintx Technologies' overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues and negative cash flows. The technical analysis provides mixed signals, with no strong trend, while the valuation is unattractive due to a negative P/E ratio and no dividend yield. These factors collectively result in a low overall stock score.
Positive Factors
Revenue Growth
The revenue growth trend indicates expanding market reach and product adoption, which can lead to improved financial stability and potential profitability over time.
Product Innovation
The focus on advanced ceramics and silicon nitride-based products positions Sintx as a leader in innovation, potentially driving long-term growth and competitive advantage.
Leadership Change
The appointment of a new Chairman can bring fresh perspectives and strategic direction, potentially enhancing governance and long-term business strategy.
Negative Factors
Rising Debt Levels
Increased leverage can strain financial resources and limit flexibility, posing risks to long-term financial health if not managed effectively.
Negative Cash Flow
Continued negative cash flow indicates challenges in sustaining operations and funding growth, which could impact long-term viability if not addressed.
Profitability Issues
Persistent profitability challenges highlight operational inefficiencies and cost management issues, which could hinder long-term growth and shareholder value.

Sintx Technologies (SINT) vs. SPDR S&P 500 ETF (SPY)

Sintx Technologies Business Overview & Revenue Model

Company DescriptionSintx Technologies (SINT) is an advanced materials company that specializes in the development and commercialization of silicon nitride ceramics, which are known for their biocompatibility and antibacterial properties. Operating primarily in the healthcare and industrial sectors, Sintx focuses on producing innovative products for medical implants, surgical instruments, and other applications that require high-performance materials. The company's flagship product is its silicon nitride technology, which is utilized in various medical devices and offers significant advantages in terms of durability and infection resistance.
How the Company Makes MoneySintx Technologies generates revenue through the sale of its silicon nitride-based products to healthcare and industrial clients. The company primarily earns money from licensing agreements, where it partners with medical device manufacturers to integrate its materials into their products. Additionally, Sintx may engage in direct product sales of its proprietary technology and components, providing a steady stream of income. Strategic partnerships with industry leaders in the medical field enhance its market reach and drive revenue growth, while ongoing research and development efforts aim to expand its product portfolio and attract new clients.

Sintx Technologies Financial Statement Overview

Summary
Sintx Technologies is facing significant financial challenges, with declining revenues, high operating losses, and negative cash flows. The balance sheet shows moderate leverage, but the negative return on equity highlights poor financial performance. The company needs to address its profitability and cash flow issues to improve its financial health.
Income Statement
30
Negative
Sintx Technologies has been experiencing declining revenues with a negative growth rate of -11.54% in the TTM. The company shows a significant net loss, with a net profit margin of -13.59% and an EBIT margin of -8.03%. Despite a decent gross profit margin of 50.04%, the overall profitability is severely impacted by high operating losses.
Balance Sheet
40
Negative
The company's debt-to-equity ratio stands at 0.82, indicating moderate leverage. However, the return on equity is negative at -367.21%, reflecting poor returns for shareholders. The equity ratio is relatively stable, suggesting some balance in asset financing.
Cash Flow
35
Negative
Sintx Technologies has a negative operating cash flow, with a concerning operating cash flow to net income ratio of -1.69. The free cash flow to net income ratio is slightly better at 1.04, but the overall cash flow situation indicates financial strain.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.22M1.25M2.63M601.00K606.00K594.00K
Gross Profit610.00K435.00K1.84M336.00K157.00K119.00K
EBITDA-9.07M-9.61M-6.60M-11.06M-8.63M-6.53M
Net Income-16.56M-11.02M-8.26M-12.04M-9.31M-7.03M
Balance Sheet
Total Assets11.36M9.41M15.37M15.77M21.84M30.45M
Cash, Cash Equivalents and Short-Term Investments6.25M3.60M3.34M6.25M14.27M25.35M
Total Debt3.39M4.03M4.76M3.63M2.91M2.28M
Total Liabilities7.30M5.52M6.59M10.07M4.64M4.64M
Stockholders Equity4.07M3.89M8.77M5.70M17.20M25.80M
Cash Flow
Free Cash Flow-7.64M-9.33M-14.64M-11.67M-13.87M-9.47M
Operating Cash Flow-7.35M-8.64M-14.12M-10.26M-10.13M-9.11M
Investing Cash Flow965.00K-194.00K-501.00K-1.10M-1.66M1.75M
Financing Cash Flow7.82M9.09M11.71M3.34M705.00K30.93M

Sintx Technologies Technical Analysis

Technical Analysis Sentiment
Positive
Last Price4.15
Price Trends
50DMA
3.81
Positive
100DMA
3.61
Positive
200DMA
3.29
Positive
Market Momentum
MACD
0.02
Negative
RSI
61.66
Neutral
STOCH
92.37
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SINT, the sentiment is Positive. The current price of 4.15 is above the 20-day moving average (MA) of 3.43, above the 50-day MA of 3.81, and above the 200-day MA of 3.29, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 61.66 is Neutral, neither overbought nor oversold. The STOCH value of 92.37 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SINT.

Sintx Technologies Risk Analysis

Sintx Technologies disclosed 42 risk factors in its most recent earnings report. Sintx Technologies reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Sintx Technologies Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
45
Neutral
$11.83M-0.31-204.04%-60.89%94.49%
44
Neutral
$9.66M-0.61-207.19%-5.19%-0.81%
44
Neutral
$10.39M-0.20-197.26%-2.47%91.23%
42
Neutral
$22.57M-0.39-62.12%-87.84%29.16%
38
Underperform
$183.36M>-0.0187.45%72.30%
37
Underperform
$29.24M-565.18%-48.74%89.18%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SINT
Sintx Technologies
4.15
0.11
2.72%
SSKN
Strata Skin Sciences
1.50
-1.58
-51.30%
HSDT
Helius Medical Technologies
4.15
-458.75
-99.10%
HIND
Vyome Holdings
5.18
-550.82
-99.07%
CODX
Co-Diagnostics
0.37
-0.57
-60.64%
TNON
Tenon Medical, Inc.
1.13
-1.15
-50.44%

Sintx Technologies Corporate Events

Private Placements and FinancingRegulatory Filings and Compliance
Sintx Technologies Announces At The Market Offering
Neutral
Oct 3, 2025

On October 3, 2025, SINTX Technologies entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC to sell shares of its common stock. This agreement allows for the sale of shares through an ‘at the market offering’ program, with Wainwright acting as the sales agent. The company is not obligated to sell any shares and can suspend the offering at any time. The agreement includes customary indemnification and contribution rights, and the shares will be issued under the company’s shelf registration statement filed with the SEC.

The most recent analyst rating on (SINT) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Sintx Technologies stock, see the SINT Stock Forecast page.

Private Placements and Financing
Sintx Technologies Enters Inducement Agreement for $3.8M
Neutral
Sep 9, 2025

On September 8, 2025, SINTX Technologies, Inc. entered into an inducement agreement with certain holders of its existing warrants to purchase shares of common stock. The agreement involves the exercise of existing warrants and the issuance of new warrants, expected to generate approximately $3.8 million in gross proceeds for the company. The company plans to use these proceeds for general corporate purposes. The transactions are expected to close on or about September 9, 2025, subject to customary conditions.

The most recent analyst rating on (SINT) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Sintx Technologies stock, see the SINT Stock Forecast page.

Executive/Board ChangesShareholder Meetings
Sintx Technologies Appoints New CFO Kevin Trask
Neutral
Sep 5, 2025

On September 4, 2025, SINTX Technologies, Inc. appointed Kevin Trask as Chief Financial Officer. Trask, who previously served as the company’s Corporate Controller, has a background in finance and accounting from various publicly traded companies. His compensation includes a salary increase, a potential bonus, and restricted stock units. The same day, SINTX held its annual stockholders meeting, where several proposals were voted on, including the election of directors and the approval of the 2025 Equity Incentive Plan. These decisions are expected to influence the company’s governance and financial strategies moving forward.

The most recent analyst rating on (SINT) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Sintx Technologies stock, see the SINT Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 26, 2025